Apontis Pharma AG provided revenue guidance for the year 2022. For the year, the Executive Board confirms its forecast of an increase in revenues of 8% to EUR 55.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.88 EUR | -1.25% | +1.29% | +68.38% |
05/04 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
28/03 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- APPH Stock
- APPH Stock
- News Apontis Pharma AG
- Apontis Pharma AG Provides Revenue Guidance for the Year 2022